Le Lézard10h
Boehringer Ingelheim and partners start clinical development of a first-in-class, inhaled gene therapy for people with cystic fibrosis
Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC)1 and OXB,1 today announce the start of LENTICLAIRTM 1, a Phase I/II trial of BI 3720931, a novel, first-in-class, gene ...
Three electric motors, a V12, and 1,001 hp—driving the Lamborghini Revuelto
This trend might seem like an existential dilemma for an automaker with a legacy built on face-melting performance, but ...